Overview

Allosterix Pharmaceuticals, LLC specializes in de novo design of biologically active peptides, peptoids and minoproteins, with a particular focus on artificial head-to-tail macrocycles incorporating non-proteinogenic amino acids - the class of compounds competing screening-based approaches cannot efficiently deliver. Allosterix employs a proprietary in silico platform, capable of pushing structure-based de novo design to its limits - in the course of a project recently executed for a pharma partner, the very first compound designed for the given target was experimentally verified to have a lead-like affinity. While such "100%" cannot be guaranteed every time, such efficiency represents a true paradigm change in drug discovery. The in-house projects at Allosterix are presently concerned with viral attachment inhibitors (HIV) and certain innovations de novo design enables. Of particular interest are macrocyclic peptides with a catalytic (cysteine protease) function, acting as protein-specific degraders. We also offer discovery partnering and consulting/contract work. There are no two identical problems, some require months of work, some other can be completed literally over the weekend. Quotes are prepared for specific projects, after we do preliminary research and assessment. The most efficient way to inquire is by directly contacting Dr. Greg Czyryca - https://www.linkedin.com/in/p-greg-czyryca-352b62b3/